These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1232 related articles for article (PubMed ID: 18343274)

  • 1. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
    Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
    J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
    Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of health care resource utilization after macrolide treatment failure: results from a large, population-based cohort with acute sinusitis, acute bronchitis, and community-acquired pneumonia.
    Wu JH; Howard DH; McGowan JE; Frau LM; Dai WS
    Clin Ther; 2004 Dec; 26(12):2153-62. PubMed ID: 15823779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
    Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to infectious diseases society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort.
    Wu JH; Howard DH; McGowan JE; Turpin RS; Henry Hu X
    Clin Ther; 2006 Sep; 28(9):1451-61. PubMed ID: 17062317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
    Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
    Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
    Jackson J; Fernandes AW; Nelson W
    Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of treating lower respiratory tract infections.
    Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
    Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
    Malcolm C; Marrie TJ
    Arch Intern Med; 2003 Apr; 163(7):797-802. PubMed ID: 12695270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
    Mokabberi R; Haftbaradaran A; Ravakhah K
    J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
    Griffin AT; Peyrani P; Wiemken T; Arnold F
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
    Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
    Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
    File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
    Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.